Showing results (21-30 of 57) with videos related to
Sort By:
Pageof 6
Cancer|May 14, 2020
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor typesHermann Einsele, Hossein Borghaei, Robert Z Orlowski, et al.International Journal of Cancer|September 5, 2002
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibodyTorsten Dreier, Grit Lorenczewski, Christian Brandl, et al.Antiviral Research|March 5, 2017
Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infectionJochen Pendzialek, Kenny Roose, Anouk Smet, et al.Cancer Immunology, Immunotherapy : CII|February 21, 2007
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructChristian Brandl, Cornelia Haas, Sandrine d'Argouges, et al.Cancer Research|October 31, 2019
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse EventsMatthias Klinger, Gerhard Zugmaier, Virginie Nägele, et al.Cancer Immunology, Immunotherapy : CII|July 3, 2008
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humansMaria Amann, Matthias Friedrich, Petra Lutterbuese, et al.Experimental Hematology & Oncology|May 24, 2017
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALLVirginie Nägele, Andrea Kratzer, Gerhard Zugmaier, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 19, 2003
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody constructTorsten Dreier, Patrick A Baeuerle, Iduna Fichtner, et al.Plos One|October 27, 2010
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsInes Herrmann, Patrick A Baeuerle, Matthias Friedrich, et al.Proceedings of the National Academy of Sciences of the United States of America|May 19, 2010
Antibody recognition of a unique tumor-specific glycopeptide antigenCory L Brooks, Andrea Schietinger, Svetlana N Borisova, et al.Pageof 6